Soumen Saha

Dr. Soumen Saha

Department of Biomedical Engineering, Duke University, Durham, NC 277018, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2020 in Advanced Therapeutics
Verified
Journal Article
Closed access
PDF file
SSSoumen Saha
Soumen Saha
SBSamagya Banskota
Samagya Banskota
SRStefan Roberts
Stefan Roberts
NKNadia Kirmani
Nadia Kirmani
ACAshutosh Chilkoti
Ashutosh Chilkoti

29 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JMJoshua James Milligan
Joshua James Milligan
SSSoumen Saha
Soumen Saha
Nanomedicines represent the cutting edge of today’s cancer therapeutics. Seminal research decades ago has begun to pay dividends in the clinic, allowing for the delivery of cancer drugs with enhanced systemic circulation while also minimizing off-target toxicity. Despite the advantages of delivering cancer drugs using nanoparticles, micelles, or other nanostructures, only a small fraction of the injected dose reaches the tumor, creating a narrow therapeutic window for an otherwise potent drug. First-pass metabolism of nanoparticles by the reticuloendothelial system (RES) has been identified as a major culprit for the depletion of nanoparticles in circulation before they reach the tumor site. To overcome this, new strategies, materials, and functionalization with stealth polymers have been developed to improve nanoparticle circulation and uptake at the tumor site. This review summarizes the strategies undertaken to evade RES uptake of nanomedicines and improve the passive and active targeting of nanoparticle drugs to solid tumors. We also outline the limitations of current strategies and the future directions we believe will be explored to yield significant benefits to patients and make nanomedicine a promising treatment modality for cancer.

1 April 2022 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
JMJoshua James Milligan
Joshua James Milligan
SSSoumen Saha
Soumen Saha
IJIrene C Jenkins
Irene C Jenkins
ACAshutosh Chilkoti
Ashutosh Chilkoti

2 April 2020 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
SSSoumen Saha
Soumen Saha
VYVenu Yakati
Venu Yakati
GSGajji Shankar
Gajji Shankar
MJMadan Mohan Chandra Sekhar Jaggarapu
Madan Mohan Chandra Sekhar Jaggarapu
GMGopikrishna Moku
Gopikrishna Moku
ACArabinda Chaudhuri
Arabinda Chaudhuri
BBB-crossing amphetamine decorated cationic lipid nanoparticle co-loaded with paclitaxel and PDL-1 siRNA enhances survivability of orthotopic glioblastoma bearing mice.

15 July 2022 in Nano Letters
Verified
Journal Article
Closed access
SSSoumen Saha
Soumen Saha
SBSamagya Banskota
Samagya Banskota
JLJianqiao Liu
Jianqiao Liu
NZNikita Zakharov
Nikita Zakharov
MDMichael Dzuricky
Michael Dzuricky
ACAshutosh Chilkoti
Ashutosh Chilkoti

26 July 2023 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
SBSugata Barui
Sugata Barui
SSSoumen Saha
Soumen Saha
YVYakati Venu
Yakati Venu
GMGopi Krishna Moku
Gopi Krishna Moku
ACArabinda Chaudhuri
Arabinda Chaudhuri
Eradicating established mouse melanoma by tumor-selective chemotherapy in combination with in vivo dendritic cell targeted genetic immunization using a tumor antigen encoded DNA vaccine.